Chemify

Rounds and research, on one timeline

1. 2026-09-16Series B extension
   Round

   Series B extended to £51.9M ($70M) in total

   For: second-generation Chemifarm, new Glasgow HQ

   Automated labManufacturing and scale-up

   A cumulative Series B figure that includes the Oct 2025 $50M+; released with £22M in grants, which are not equity. Company says total funding secured is over £110M ($150M).

   No investor named in the source.

   By this date the record held 3 research entries, highest level 4

   Announced by the company · 01net.it ↗

2. 2026-04-07
   Research

   Level 3 · Checked against existing evidence

   Lee Cronin, Chemify's founder, argues in PNAS that a Chemputer with step-by-step error correction could in principle make any stable molecule, and re-reads 117 robot runs to back it

   If synthesis is code, a route can be shared, compiled for different machines and checked automatically, the way software is. This is Cronin's formal case for programmable synthesis, and it names the obstacle: errors pile up over many steps, so the claim rests on catching and fixing them while each step runs.

   Timeline entry →doi.org ↗

3. 2026-04-03
   Research

   Level 4 · Tested in the physical world

   An LLM agent from Cronin's group, whose founder leads Chemify, turns published procedures into robot code and runs six of them

   The backlog the paper is aimed at is the published literature itself: procedures nobody has repeated, written ambiguously. If an agent can turn a paper's method into a script a robot executes, repeating a synthesis costs machine time rather than a chemist's week, and the one procedure here that would not work was found by running it.

   Timeline entry →doi.org ↗

4. 2026-03-27
   Research

   Level 4 · Tested in the physical world

   Cronin's group, whose founder leads Chemify, makes kinase inhibitors on a Chemputer and finds one that beats regorafenib in colorectal organoids

   A robot-made molecule got through two rounds of design and testing. Evidence stops at flies and organoids, one lab's own work, and read from the abstract only.

   Timeline entry →doi.org ↗

5. 2026-02-12Strategic
   Round

   undisclosed

   For: alongside a deal to make compounds and materials for Zeon

   Commercial roll-outManufacturing and scale-up

   Whether this counts inside the Series B extension below is not stated.

   Lead · Zeon Ventures ✓

   On the deal: Kazuhiro Takahashi (Representative, Zeon Ventures)

   The investor's own page says · Zeon Ventures: 2026-02-12 strategic investment

   Reported by European Biotechnology Magazine · european-biotechnology.com ↗

6. 2025-10-21Series B
   Round

   more than $50M

   For: scale Chemputation and the Chemifarm facilities

   Automated labManufacturing and scale-up

   Co-lead · Wing Venture Capital ✓Co-lead · Insight Partners ✓8VCTriatomic Capital ✓Blueyard ✓RockspringEos

   On the deal: Aiden Aceves (Vice President, Insight Partners, joins the board); Ansuman Satpathy (Partner, Wing Venture Capital, joins the board)

   The investor's own page says · Blueyard: seed

   The investor's own page says · Insight Partners: Series B (co-lead)

   The investor's own page says · Wing Venture Capital: Series B

   Announced by the company · insightpartners.com ↗

7. 2023-08-03Series A
   Round

   $43M

   For: grow the company and its platform

   Hiring

   Tech.eu reports it with Lee Cronin quoted; the University of Glasgow gives it as £36M.

   Lead · Triatomic Capital ✓Horizon VenturesPossible VenturesAlix VenturesEosBlueYard Capital ✓UK Government Innovation AcceleratorsRocketship Ventures

   Announced by the company · tech.eu ↗

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →